Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccine for inducing an improved immune reaction

A vaccine and antigen technology, applied in the field of immune response vaccine composition, can solve the problem of negligible effect

Inactive Publication Date: 2013-11-06
EYEGENE INC
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In particular, in the case of monophosphoryl lipid A (MPL, monophosphoryl lipid) obtained by phosphorylation of lipid A obtained by eliminating LPS glycan chains, it has been developed as an immune anticancer agent that eliminates the toxicity of LPS, but its The effect is negligible ( http: / / www.corixa.com )

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine for inducing an improved immune reaction
  • Vaccine for inducing an improved immune reaction
  • Vaccine for inducing an improved immune reaction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0084] Hereinafter, the present invention will be described in more detail through examples. These embodiments are only to describe the present invention in more detail. According to the gist of the present invention, the scope of protection claimed by the present invention is not limited to these embodiments, which is obvious to those of ordinary skill in the technical field of the present invention .

[0085] 【Example】

Embodiment 1

[0086] [Example 1: Production of very short lipooligosaccharide (LOS) CIA05 as a new immune adjuvant]

[0087]The present inventors have discovered a lipopolysaccharide strain (E. coli EG0021) having a very short sugar chain length of lipooligosaccharide from Escherichia coli living in the intestinal tract of healthy humans, and published on May 2, 2002 , entrusted this strain to the depository organization - Korea Microorganism Storage Center, and obtained the deposit number KCCM10374 (reference: Korean Patent Grant No. 0456681; WO2004 / 039413; Korean Patent Grant No. 0740237; WO2006 / 121232). Purification of lipopolysaccharide from the above strains was performed according to the methods disclosed in Korean Patent Grant No. 0456681; WO2004 / 039413; Korean Patent Grant No. 0740237; WO2006 / 121232. The molecular weight of the purified lipopolysaccharide was measured by MALDI-MASS (Shimadz Corporation, Axima-LNR V2.3.5 (Mode Liner, Power: 106)). As a result of the measurement, it w...

Embodiment 2

[0088] [Example 2: Comparative experiment on toxicity between the new immune adjuvant CIA05 and the existing immune adjuvant monophospholipid A]

[0089] The toxicity of CIA05 prepared in the above examples used as immune adjuvant in the vaccine of the present invention and the monophospholipid A used in the existing cervical cancer vaccine was compared and analyzed. Receive blood from healthy people to isolate peripheral blood mononuclear cells (PBMC, Peripheral Blood Mononuclear Cell), in 24-well culture dishes with 5×10 5 The above-mentioned peripheral blood mononuclear cells were cultured at a concentration of cell / ml. At this time, a culture solution obtained by mixing 10% fetal bovine serum (FBS, fetal calf serum; Gibco) with RPMI1640 (Gibco) was used, and the volume of each well was divided into 1 ml. The prepared Petri dishes were individually processed under the following conditions. 1) Negative control group: Balanced salt solution (BBS, Balanced salt solution) 100...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.

Description

【Technical field】 [0001] The present invention relates to a vaccine composition that induces an improved immune response. 【Background technique】 [0002] Recently, immune adjuvants have attracted much attention and have been used in various ways for cervical cancer vaccines and influenza vaccines, etc. Bacterial DNA in this type of immune adjuvant has attracted attention as an anticancer agent since the 1960s, and research continues until now, but it cannot be used alone as an anticancer agent due to insufficient efficacy (Glick, J.L. The specificity of inhibition of Tumor cell viability by DNA. Cancer Res. 27:2338, 1967). But it is well known that bacterial DNA has no major side effects and can activate various immune cells, especially, it has many advantages as an adjuvant (McCluskie MJ, et al..CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. JImmunol. Nov1; 161 (9): 4463-6.1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/29A61K39/145A61K39/12A61P1/16
CPCA61K39/07A61K39/292A61K39/245A61K39/21A61K39/12A61K39/29A61K39/145A61K39/25A61K39/39A61K39/095A61K39/0018A61K39/04A61K39/102A61K2039/55572C12N2710/16634C12N2710/16734C12N2730/10134C12N2740/16034C12N2760/16134C12N2770/24234C12N2770/32434A61P1/16A61P31/00A61P31/04A61P31/06A61P31/16A61P31/22A61P37/02A61P37/04
Inventor 赵良济李奈暻张镇旭金光成俞元一
Owner EYEGENE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com